Liu H N, Larocca J N, Almazan G
Department of Pharmacology and Therapeutics, McGill University, Room 1321, 3655 Drummond St., Montreal, Quebec, Canada.
Brain Res Mol Brain Res. 1999 Mar 20;66(1-2):50-61. doi: 10.1016/s0169-328x(99)00009-1.
Oligodendroglial cells express ionotropic glutamate receptors of alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid hydrobromide (AMPA) and kainate (KA) subtypes. Recently, we reported that AMPA receptor agonists increased 45Ca2+ uptake and phospholipase C (PLC) activity. To further elucidate the intracellular signaling mechanisms, we examined the effects of AMPA and KA on mitogen-activated protein kinase (MAPK). KA caused a time- and concentration-dependent increase in MAPK activity (predominantly the p42mapk or ERK2) and the effect was blocked by 6-cyano-7-nitro-quinoxaline-2,3-dione (CNQX), a competitive AMPA/KA receptor antagonist. Furthermore, the noncompetitive antagonists of AMPA receptor GYKI 52466 and LY 303070 prevented the actions of the agonists, indicating that the effect of KA on MAPK activation is mediated through AMPA receptors in oligodendrocyte progenitors. Chelation of extracellular Ca2+ by EDTA or inhibition of PLC with U73122 abolished MAPK activation by KA. In addition, KA-stimulated MAPK activation was reduced by the protein kinase C (PKC) inhibitors, H7 and bisindolylmaleimide, as well as downregulation of PKC by prolonged exposure to phorbol esters. The involvement of PKC in the signal transduction pathways was further supported by the ability of KA to induce translocation of PKC measured by [3H]PDBu binding. Interestingly, a wortmannin-sensitive phosphatidylinositol 3-kinase and a pertussis toxin (PTX)-sensitive G protein form part of the molecular pathways mediating MAPK activation by AMPA receptor. A specific inhibitor of MAPK kinase, PD 098059, blocked MAPK activation and reduced KA-induced c-fos gene expression. All together, these results indicate that MAPK is implicated in the transmission of AMPA signaling to the nucleus and requires extracellular Ca2+, and PLC/PKC activation.
少突胶质细胞表达α-氨基-3-羟基-5-甲基异恶唑-4-丙酸氢溴酸盐(AMPA)和海人藻酸(KA)亚型的离子型谷氨酸受体。最近,我们报道AMPA受体激动剂可增加45Ca2+摄取和磷脂酶C(PLC)活性。为了进一步阐明细胞内信号转导机制,我们研究了AMPA和KA对丝裂原活化蛋白激酶(MAPK)的影响。KA引起MAPK活性呈时间和浓度依赖性增加(主要是p42mapk或ERK2),且该效应被竞争性AMPA/KA受体拮抗剂6-氰基-7-硝基喹喔啉-2,3-二酮(CNQX)阻断。此外,AMPA受体的非竞争性拮抗剂GYKI 52466和LY 303070可阻止激动剂的作用,表明KA对MAPK激活的作用是通过少突胶质前体细胞中的AMPA受体介导的。用EDTA螯合细胞外Ca2+或用U73122抑制PLC可消除KA对MAPK的激活。此外,蛋白激酶C(PKC)抑制剂H7和双吲哚马来酰胺以及通过长期暴露于佛波酯使PKC下调可降低KA刺激的MAPK激活。KA诱导的PKC转位能力通过[3H]佛波醇-12,13-二丁酸酯(PDBu)结合来测定,这进一步支持了PKC参与信号转导途径。有趣的是,一种渥曼青霉素敏感的磷脂酰肌醇3-激酶和一种百日咳毒素(PTX)敏感的G蛋白构成了介导AMPA受体激活MAPK的分子途径的一部分。MAPK激酶的特异性抑制剂PD 098059可阻断MAPK激活并降低KA诱导的c-fos基因表达。总之,这些结果表明MAPK参与AMPA信号向细胞核的传递,并且需要细胞外Ca2+以及PLC/PKC激活。